BMJ Open (Jun 2023)

Oral-only antibiotics for bone and joint infections in children: study protocol for a nationwide randomised open-label non-inferiority trial

  • ,
  • Ulrikka Nygaard,
  • Kim Kristensen,
  • Lone Graff Stensballe,
  • Kjeld Schmiegelow,
  • Morten Søndergaard Lindhard,
  • Mads Damkjær,
  • Allan Bybeck Nielsen,
  • Luise Borch,
  • Jonathan Peter Glenthøj,
  • Ulla Hartling,
  • Thomas Ulrik Hoffmann,
  • Mette Holm,
  • Annett Helleskov Rasmussen,
  • Lisbeth Samsø Schmidt,
  • Grethe Lemvik Mikkelsen,
  • Jens Jakob Herrche Petersen,
  • Jesper Thaarup,
  • Lise Heilmann Jensen,
  • Marie Cecilie Lawaetz,
  • Pawel Andrej Marcinski,
  • Lotte Høeg Hansen,
  • Tanja Hübertz Horsager,
  • Tatjana Zaharov,
  • Jakob Hjort,
  • Ulrik Justesen,
  • Maren Rytter

DOI
https://doi.org/10.1136/bmjopen-2023-072622
Journal volume & issue
Vol. 13, no. 6

Abstract

Read online

Introduction Children with bone and joint infections are traditionally treated with intravenous antibiotics for 3–10 days, followed by oral antibiotics. Oral-only treatment has not been tested in randomised trials.Methods and analysis Children (3 months to 18 years) will be randomised 1:1 with the experimental group receiving high-dose oral antibiotics and the control group receiving intravenous antibiotics with a shift in both groups to standard oral antibiotics after clinical and paraclinical improvement. Children in need of acute surgery or systemic features requiring intravenous therapy, including septic shock, are excluded. The primary outcome is defined as a normal blinded standardised clinical assessment 6 months after end of treatment. Secondary outcomes are non-acute treatment failure and recurrent infection. Outcomes will be compared by a non-inferiority assumption with an inferiority margin of 5%.Ethics and dissemination The trial has the potential to reduce unnecessary hospitalisation and use of intravenous antibiotics in children with bone or joint infections. Due to the close follow-up, exclusion of severely ill children and predefined criteria for discontinuation of the allocated therapy, we expect the risk of treatment failure to be minimal.Trial registration number NCT04563325.